Novo Nordisk will maintain an attractive dividend per share; Novo Nordisk aims to serve more than 60 million patients globally by 2030; Novo Nordisk plans to maintain a generally stable operating margin; and Novo Nordisk targets pipeline product sales exceeding DKK 150 billion by 2035.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.